Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Insight Molecular Diagnostics (IMDX) Deferred Taxes (2020 - 2021)

Insight Molecular Diagnostics' Deferred Taxes history spans 2 years, with the latest figure at $97000.0 for Q4 2021.

On a quarterly basis, Deferred Taxes rose 161.01% to $97000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was -$9.3 million, a 638.52% decrease, with the full-year FY2021 number at -$9.3 million, down 638.52% from a year prior.
Deferred Taxes hit $97000.0 in Q4 2021 for Insight Molecular Diagnostics, up from -$1.8 million in the prior quarter.
Over the last five years, Deferred Taxes for IMDX hit a ceiling of $97000.0 in Q4 2021 and a floor of -$7.6 million in Q1 2021.